Johnson, M.J., Garcia-Romeu, A., Johnson, P.S. & Griffiths, R.R. Saleemi, S., Pennybacker, S.J. Jesse, R. and Griffiths, R.R. Johnson, M.W., MacLean, K.A., Caspers, M.J., Prisinzano, Griffiths, R.R. Please feel free to check back for status of the study in the meantime. (2015) Psychedelic medicine: a re-emerging therapeutic paradigmMacLean, K.A., Johnson, M.W., & Griffiths, R.R. Volunteers will additionally receive free counseling. Researchers at Johns Hopkins University are studying psilocybin – a psychoactive substance found in certain kinds of mushrooms – to see whether it can help people with depression and Alzheimer’s Disease when administered in a safe and supportive setting. Caspers, M.J., Williams, T.D., Lovell, K.M. (2015). Roland Griffiths, Ph.D., is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, and founding Director of the Johns Hopkins Center on Psychedelic and Consciousness Research. Johnson MW. These researchers have also expanded the field of psychedelic research by publishing safety guidelines that have helped gain approval for psychedelic studies at other universities around the world and by developing new ways of measuring mystical, emotional, and meditative experiences while under the influence of psychedelics.The group's findings on both the promise and the risks of psilocybin in particular helped create a path forward for the chemical's potential medical approval and reclassification from a Schedule I drug, the most restrictive federal government category, to a more appropriate level. Griffiths, R.R., Johnson, M.W., Richards, W.A., Richards, B.D., Jesse, R., MacLean, K.A., Barrett, F.S., Cosimano, M.P., & Klinedinst, M.A. Griffiths, R.R., Johnson, M.W., Carducci, M.A., Umbricht, A., Richards, W.A., Richards, B.D., Cosimano, M.P., & Klinedinst, M.A. Sepeda, N.D., Clifton, J.M., Doyle, L.Y., Lancelotta, R., Griffiths, R.R., & Davis, A.K.
Barrett, F.S., Carbonaro, T.M., Hurwitz, E., Johnson, M.W., & Griffiths, R.R. The Center for Psychedelic and Consciousness Research will focus on how psychedelics affect behavior, brain function, learning and memory, the brain's biology, and mood. You could be eligible to participate in a psychedelic research trial. Garcia-Romeu, A., Davis, A.K., Erowid, E., Erowid, F., Griffiths, R.R., & Johnson, M.W. The university, with the help of private investors, wants to see if psychedelics like magic mushrooms can help treat diseases like PTSD, addiction, and Alzheimer's. Johns Hopkins has launched a research center that will study the therapeutic properties of psychedelic drugs. "Griffiths, who initiated the psilocybin research program at Johns Hopkins almost 20 years ago, leading the first studies investigating the effects of its use by healthy volunteers. Healthy Volunteers Needed for Research Study at Johns Hopkins Bayview. (2013). (2011). Hendricks, P.S., Thorne, C.B., Clark, C.B., Coombs, D.W., &, Johnson, M.W. "I sincerely hope this ambitious Johns Hopkins center will inspire others to think big and establish more psychedelic research centers in the U.S. and overseas, as there's never been a better time to support such important work. Help DAV: Support, Volunteer, Advocate. "The center's establishment reflects a new era of research in therapeutics and the mind through studying this unique and remarkable class of pharmacological compounds," says At Johns Hopkins, much of the early work with psychedelics has focused on psilocybin, the chemical found in so-called magic mushrooms. Psilocybin was classified as Schedule I during the Nixon administration, but the team's research over the last decade has shown psilocybin to have low toxicity and abuse potential. Institute, Signant Health, The Emmes Company, LLCLocation: San Francisco, CA; New Haven, CT; Lauderhill, Director, Center for Psychedelic and Consciousness Research Garcia-Romeu, A. Davis, A.K., Erowid, F., Erowid, E., Griffiths, R.R., & Johnson, M.W. The first research center of its kind in the country is bringing renewed rigor to … Garcia-Romeu, A., Griffiths, R.R., & , Johnson, M.W. Neuroscience & Biobehavioral Reviews, 113, 179-189 Neuroscience & Biobehavioral Reviews, 113, 179-189 Lancelotta, R & Davis, A.K. (2020). Davis, A.K., Clifton, J.M., Weaver, E.G., Hurwitz, E.H., Johnson, M.W., & Griffiths, R.R. (2008). (2016). After the drug is approved and sold in the consumer market, research continues in phase 4 known as post marketing surveillance trials. (2020). (2013).
Researchers hope to create precision medicine treatments tailored to individual patients' specific needs.